Pomalidomide for Multiple Myeloma – National Cancer Institute

 

Otto Kahler (Photo credit: Wikipedia)

 

 

 

Multiple myeloma
Classification and external resources
Micrograph of a plasmacytoma, the histologiccorrelate of multiple myeloma. H&E stain
ICD–10	C90.0
ICD–9	203.0
ICD-O:	M9732/3
OMIM	254500
DiseasesDB	8628
MedlinePlus	000583
eMedicine	med/1521
MeSH	D009101

 

Pomalidomide

Systematic (IUPAC) name
4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Clinical data
Trade names	Imnovid, Pomalyst
Licence data	EMA:Link, US FDA:link
Pregnancy cat.	X (US)
Legal status	POM (UK) ℞-only (US)
Routes	Oral
Pharmacokinetic data
Protein binding	12–44%
Metabolism	Hepatic (mostly CYP1A2 andCYP3A4 mediated; some minor contributions by CYP2C19 andCYP2D6)
Half-life	7.5 hours
Excretion	Urine (73%), faeces (15%)
Identifiers
CAS number	19171-19-8
ATC code	L04AX06
PubChem	CID 134780
ChemSpider	118785
UNII	D2UX06XLB5
ChEMBL	CHEMBL43452
Chemical data
Formula	C13H11N3O4
Mol. mass	273.24 g/mol
SMILES[show]
InChI

 

Related articles

 

• Celgene’s Pomalidomide Helps in Myeloma After Others Fail
• Celgene wraps promising PhIII data on new multiple myeloma challenger
• New drug improves survival in multiple myeloma relapse

 

 

Cancer Death Risk Greater for Men

US researchers say men diagnosed with cancer are more likely to die from the disease than women. They attribute the discrepancy in part to the fact that men are at greater risk of developing cancer than women, perhaps as a result of differences in exposure to carcinogens or hormonal or metabolic differences. According to the American Cancer Society, men have about a 1 in 2 chance of developing cancer, while women have just a 1 in 3 chance. In addition, men are more likely than women to have advanced disease by the time their cancer is detected. More… Discuss

Related articles

• Men with cancer have higher death rates than women (sfgate.com)
• Men more likely to die of cancer (cnn.com)
• Men Have Higher Cancer Death Rates Than Women (webmd.com)